Saturday 17 October 2026 Export BNGO’s income statement to Excel — free account

Bionano Genomics, Inc.

BNGO Healthcare Medical Instruments & Supplies

Bionano Genomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.5 million, down 7.37% from fiscal 2024. In the quarter to June 2026, revenue grew 21.4%, EPS grew 67.8%, free cash flow fell 33.9% and total debt fell 1.91%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.25 0.12 −8.76%

Follow BNGO

Alert me

Market cap: $16.1M
P/E: 0.0×
Fwd P/E: −0.6×
Dividend yield: —
F-score: 5/9
Altman Z: −14.26
Beneish M: −3.39
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total buys 0.01

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	1	1	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 4.04%

Capital & Financial Ratios $m

Market Cap 16.13

Revenue 30.18

Net Income (32.16)

Free Cash Flow (20.48)

Net Debt (6.98)

Current Ratio 2.48

Debt/Equity 0.11

P/E ratio 0.00

Fwd P/E (0.55)

P/S ratio 0.48

P/B ratio 0.46

Past 5Y EPS Growth —

This Y EPS Growth 67.10%

Next Y EPS Growth 54.67%

Next Y revenue growth 12.74%

Next 5Y EPS Growth 56.92%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 19.14%

10-year low 10-year high

P/B against its own 10 years 31.71%

10-year low 10-year high

EV/Sales against its own 10 years 24.60%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2018	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	102	20	30	10
Receivables	9	5	5	4
Inventory	23	11	5	5
Other	—	—	—	—
	140	39	45	25

	2023	2024	2025	Q'26
Payables	10	7	6	5
ST’ Debt	—	—	—	—
Other	9	1	1	1
	100	37	23	10

Compound Annual Growth %

	10y	5y	3y
Sales	—	27.37%	0.84%
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	4.84%	(43.73%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	7	8	—	—	—
’25	6	7	7	8	29
’24	9	8	6	8	31
’23	7	9	9	11	36
’22	6	7	7	8	28
’21	3	4	5	6	18
’20	1	1	2	4	9

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(5)	—	—	—
’25	(3)	(3)	(6)	(4)	(16)
’24	(28)	(21)	(13)	(7)	(69)
’23	(32)	(37)	(26)	(30)	(125)
’22	(32)	(28)	(29)	(35)	(125)
’21	(14)	(12)	(20)	(26)	(72)
’20	(8)	(7)	(11)	(12)	(38)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(6)	(5)	—	—	—
’25	(3)	(3)	(6)	(4)	(16)
’24	(28)	(21)	(13)	(7)	(69)
’23	(33)	(37)	(26)	(31)	(127)
’22	(33)	(29)	(30)	(36)	(127)
’21	(14)	(12)	(20)	(26)	(73)
’20	(8)	(7)	(11)	(12)	(38)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.76)	(0.64)	—	—	—
’25	(1.15)	(1.99)	(1.59)	(0.03)	(4.85)
’24	(35.93)	(14.37)	(31.14)	(7.06)	(88.13)
’23	(71.86)	(74.25)	(192.81)	(68.45)	(407.78)
’22	(65.87)	(65.87)	(65.87)	(77.84)	(275.45)
’21	(23.95)	(41.92)	(41.92)	(47.90)	(155.69)
’20	(179.64)	(53.89)	(47.90)	(35.93)	(233.53)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	2,406.00	300.00	150.00	1,728.00	696.00	71.40	11.40	1.45	Analyst estimates 2026–2028 Powerpack
	High	—	—	6,000.00	3,744.00	2,082.00	9,414.00	2,610.00	1,212.00	129.60	22.80
People
People	Employees	—	65	77	97	147	299	405	344	100	97
	Revenue/emp, $m	0.00	0.15	0.16	0.10	0.06	0.06	0.07	0.10	0.31	0.29
Income, $m
Income, $m	Revenue	7	10	12	10	9	18	28	36	31	29
	Gross margin, %	47.32	36.55	27.41	33.18	32.61	21.54	21.38	26.49	1.23	46.25
	EBT	(19)	(23)	(18)	(30)	(41)	(78)	(131)	(232)	(112)	(26)
	EBT margin, %	(277.29)	(245.63)	(154.00)	(294.13)	(483.09)	(434.64)	(470.15)	(643.57)	(363.87)	(92.35)
	Net income	(19)	(23)	(18)	(30)	(41)	(72)	(133)	(232)	(112)	(26)
	Depreciation	1	2	1	1	1	4	10	91	33	9
Per share, $
Per share, $	Revenue	67,928.00	2,112.22	1,017.01	405.18	48.84	38.90	57.56	63.47	24.21	5.24
	Earnings	(187,102.70)	(5,180.02)	(1,562.87)	(1,191.62)	(233.53)	(155.69)	(275.45)	(407.78)	(88.13)	(4.85)
	Cash flow	(234,964.00)	(4,626.18)	(1,690.16)	(1,181.19)	(220.07)	(155.62)	(258.42)	(220.00)	(54.23)	(3.00)
	Capex	(13,499.00)	(226.18)	(28.11)	(2.44)	0.00	(1.78)	(5.14)	(2.97)	(0.08)	0.00
	Free cash flow	(248,463.00)	(4,852.36)	(1,718.27)	(1,183.63)	(220.07)	(157.40)	(263.56)	(222.97)	(54.31)	(3.00)
	Book value	(272,590.00)	(11,161.60)	859.10	144.55	201.50	729.38	516.35	168.99	27.83	8.16
	Shares, m	0	0	0	0	0	0	0	1	1	5
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	0.00	0.00	3.09	1.84	37.84	46.11	15.01	1.89	0.72	0.29
	P/B	0.00	0.00	3.66	5.15	9.17	2.46	1.67	0.71	0.63	0.19
	EV/Sales	0.00	0.00	2.52	3.96	36.91	33.17	11.58	(0.44)	0.63	(0.12)
	EV/FCF	(0.69)	(0.69)	(1.49)	(1.36)	(8.18)	(8.20)	(2.53)	0.12	(0.28)	0.21
Cash, $m
Cash, $m	Operating cash flow	(23)	(21)	(20)	(30)	(38)	(72)	(125)	(125)	(69)	(16)
	Capex	(1)	(1)	0	0	—	(1)	(2)	(2)	0	—
	Free cash flow	(25)	(22)	(20)	(30)	(38)	(73)	(127)	(127)	(69)	(16)
Balance, $m
Balance, $m	Working capital	1	(10)	19	2	38	251	121	40	2	22
	Total debt	7	7	9	20	16	4	4	4	4	3
	Net debt	1	6	(7)	3	(22)	(247)	(110)	(98)	(17)	(26)
	Shareholders’ equity	(27)	(50)	10	4	35	337	249	96	35	44
Returns, %
Returns, %	ROA	(151.19)	(187.43)	(105.85)	(108.40)	(90.68)	(33.11)	(38.74)	(89.09)	(76.97)	(35.13)
	ROIC	0.00	0.00	(482.56)	(253.19)	(185.94)	(53.45)	(58.86)	0.00	(352.46)	(113.43)
	ROE	48.65	60.31	92.27	(433.64)	(212.46)	(38.92)	(45.21)	(134.56)	(170.33)	(66.15)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
HBIO Harvard Bioscience, Inc.	$37.8M	— (loss-making)	— (loss-making)	+11.13% (above 0%: growing)	n/m	−123.43% (below 0%: shrinking)	55.57%	(4.30%)	Compare
MLSS Milestone Scientific, Inc.	$29.6M	— (loss-making)	— (loss-making)	+22.27% (above 0%: growing)	n/m	+66.68% (above 0%: growing)	67.24%	(37.37%)	Compare
RVP Retractable Technologies, Inc.	$17.6M	— (loss-making)	11.1×	−31.07% (below 0%: shrinking)	n/m	+56.67% (above 0%: growing)	2.65%	(71.46%)	Compare
BNGO Bionano Genomics, Inc.	$16.1M	— (loss-making)	— (loss-making)	+21.36% (above 0%: growing)	n/m	−33.93% (below 0%: shrinking)	52.80%	(88.34%)
NXGL NexGel, Inc.	$15.9M	— (loss-making)	— (loss-making)	+27.81% (above 0%: growing)	n/m	−432.32% (below 0%: shrinking)	30.09%	(67.96%)	Compare
FEMY Femasys Inc.	$14.5M	— (loss-making)	— (loss-making)	−18.93% (below 0%: shrinking)	n/m	+11.29% (above 0%: growing)	57.08%	(1,526.79%)	Compare
CUPR Cuprina Holdings (Cayman) Limited	$11.5M	—	—	—	—	—	—	—	Compare
RGNT Regentis Biomaterials Ltd.	$10.9M	—	—	—	—	−132.79% (below 0%: shrinking)	—	—	Compare
LUCY Innovative Eyewear, Inc.	$7.3M	— (loss-making)	—	+74.46% (above 0%: growing)	n/m	+9.61% (above 0%: growing)	24.00%	(168.73%)	Compare
Median of peers	$15.2M	—	—	+16.70%	—	+9.61%	42.83%	(69.71%)

All 55 Medical Instruments & Supplies stocks →

Bionano Genomics, Inc. (BNGO) key facts

Concern: Bionano Genomics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $28.5 million, down 7.37% from fiscal 2024.
Bionano Genomics, Inc. (BNGO) is a Medical Instruments & Supplies company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, BNGO traded at $1.25, a market capitalization of $16.1 million.
Return on equity was −66.2% and debt-to-equity 0.11.
Its Piotroski F-score is 5 out of 9 and its Altman Z-score is −14.26 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.